Reduced Use of the Systemic Corticosteroids and Improved Quality of Life under Treatment with Beclometasone/Formoterol/Glycopyrronium in Asthma Patients: First Key Results from TriMaximize Study

Rationale: When needed, systemic corticosteroids (SCS) are an effective treatment for acute exacerbations and long-term symptom control in asthma. However, cumulative exposure to SCS is associated with an increased risk of serious adverse events and a negative impact on patient’s quality of life. The use of SCS under fixed triple therapy with beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) in asthma patients has been insufficiently investigated in real-world settings. The TriMaximize study was designed to also provide valuable insights into this important clinical aspect of asthma treatment. Methods : TriMaximize is a multinational, observational study following asthma patients prescribed BDP/FF/G over one to three years. Patients were recruited at 165 sites across Germany, United Kingdom, Austria, Denmark, France, Spain, Poland and Italy. Health-Related Quality of Life is evaluated by Mini Asthma Quality of Life Questionnaire (Mini AQLQ). Data were analyzed descriptively. Results : In total, 1, 445 patients (62.8% female; mean age: 57.6 years) were included in the study. The majority (72.7%) had previously been treated with ICS/LABA (fixed or free) and 27.3% with ICS/LABA/LAMA (fixed or free). At baseline, 33.2% of the patients had used SCS within the last year under their previous treatment. After 12 months of treatment with BDP/FF/G, the use of SCS has declined to 12.4% and after 36 months to 13.7%. The mean baseline Mini AQLQ score of 4.2 points improved by 0.8 points in the first year (n=543, p